Snapshot img

Drug Discovery Technology Market Size 2024-2028

The drug discovery technology market size is forecast to increase by USD 27.31 billion, at a CAGR of 9.2% between 2023 and 2028.

The market is witnessing significant growth due to the increasing prevalence of chronic diseases worldwide. The growing burden of diseases such as cancer, neurological disorders, and cardiovascular diseases necessitates the development of innovative drug discovery technologies. One such technology is Artificial Intelligence (AI) and Machine Learning (ML) in drug discovery, which is revolutionizing the industry by enabling the analysis of vast amounts of data to identify potential drug candidates. Another technology, RNA interference (RNAi), offers a novel approach to drug development by targeting specific genes to treat diseases. However, the market faces challenges that hinder its growth. Intellectual property (IP) issues are a significant obstacle, with the increasing number of patents and licensing agreements complicating the development and commercialization of new therapies. Additionally, the high cost of drug discovery and development, coupled with the lengthy regulatory approval process, creates a complex landscape for market participants. Despite these challenges, opportunities exist for companies to capitalize on the market's potential. Collaborations and partnerships between academia, biotech, and pharmaceutical companies can help reduce the financial burden and accelerate the development process. Furthermore, the integration of emerging technologies such as AI, ML, and RNAi can enhance the efficiency and effectiveness of drug discovery efforts, ultimately leading to the development of novel therapies for various diseases.

What will be the Size of the Drug Discovery Technology Market during the forecast period?

Request Free SampleThe market is a dynamic and evolving landscape, with ongoing advancements and innovations shaping its contours. Biotechnology companies are at the forefront of this progress, leveraging various technologies to tackle complex therapeutic areas such as rare diseases and cancer. Machine learning algorithms, including deep learning, are increasingly utilized for data analysis and lead optimization, enhancing the drug discovery process. Clinical trials continue to play a pivotal role in bringing new therapies to market, with a focus on improving trial design and management for greater efficiency and accuracy. Intellectual property protection remains crucial, with patent protection and licensing agreements shaping the drug development pipeline. Cancer therapeutics and metabolic disorders therapeutics are among the most active areas of research, with a growing emphasis on personalized medicine and protein engineering. Cardiovascular disease therapeutics and antibody-drug conjugates (ADCs) are also attracting significant attention, with advances in drug delivery systems and drug resistance. Artificial intelligence and quantum mechanics calculations are transforming drug discovery, enabling drug repurposing, drug safety assessments, and target identification. Regulatory approval processes are evolving to accommodate these advancements, with a focus on precision medicine and health economics. The market for orphan drugs and infectious disease therapeutics is expanding, driven by a growing understanding of the underlying genetic and molecular causes of these conditions. Neurological disorders therapeutics are also gaining traction, with advances in gene editing and molecular dynamics simulations. Drug pricing, drug accessibility, and drug reimbursement remain key challenges, with ongoing debates surrounding affordability and equity. The market for drug discovery platforms and ligand-based drug design is growing, with a focus on improving drug efficacy, drug toxicity, and drug interaction predictions. The drug discovery process is a complex and intricate endeavor, with ongoing research and innovation shaping its future. From target identification to regulatory approval, the market dynamics are constantly unfolding, with new technologies and applications emerging to address the challenges of discovering and developing new therapies.

How is this Drug Discovery Technology Industry segmented?

The drug discovery technology industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductGenomicsProteomicsBioinformaticsHigh-throughput screening (HTS)OthersEnd-userPharmaceutical and biotechnology companiesAcademic and research institutesCROsGeographyNorth AmericaUSEuropeFranceGermanyUKAPACChinaRest of World (ROW)

By Product Insights

The genomics segment is estimated to witness significant growth during the forecast period.The biotechnology industry is experiencing significant growth in the mark

Global Artificial Intelligence in Drug Discovery Market was valued at USD 1.2 Billion in 2023 and expected to reach USD 13.6 Billion by 2033

By 2031, the in-silico drug discovery market worldwide is expected to be valued at *** billion U.S. dollars. As of 2021, the market was valued at just *** billion U.S. dollars. The largest segment of the in-silico drug discovery market is software as a service (SaaS). 'In-silico' in general means that testing is done by computer simulation, as in contrast to 'in vivo' or 'in vitro'. In-silico testing was used, for example, in the search for existing drugs which could potentially be used as therapy or cure for COVID-19. In-silico is believed to have great potential for speeding up drug discovery because expensive laboratory work and clinical trials could be reduced.

The Drug Discovery Informatics Market Report is Segmented by Function (Sequencing & Target Data Analysis, and More), End User (Pharmaceutical Companies, and More), Solution (Software and Services), Workflow (Discovery Informatics and Development Informatics), Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Snapshot img

Artificial Intelligence In Drug Discovery Market Size 2025-2029

The artificial intelligence in drug discovery market size is forecast to increase by USD 4.32 billion at a CAGR of 25.7% between 2024 and 2029.

Artificial Intelligence (AI) is revolutionizing the drug discovery market, offering significant potential for accelerating the development of new therapies. Key growth factors include the availability of funding and strategic partnerships between industry players and tech companies. However, regulatory hurdles pose a challenge, as AI applications in drug discovery must meet stringent regulatory requirements.
Additionally, the use of AI in drug discovery is trending, with its ability to process vast amounts of data and identify potential drug candidates more efficiently than traditional methods. This market analysis report provides an in-depth examination of these factors and their impact on the drug discovery market's growth trajectory. AI's potential to transform the pharmaceutical industry is undeniable, and this report offers valuable insights into the opportunities and challenges associated with its adoption. AI-powered safety monitoring systems ensure that drugs meet professional certifications and regulatory requirements, while medical devices and medical diagnostics benefit from AI for biopharma in target identification and AI certification for professional standards.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

Artificial Intelligence (AI) is revolutionizing the drug discovery market by offering innovative solutions to optimize various stages of the drug development lifecycle. From drug structure optimization to clinical trial optimization, AI is transforming the way new drugs are discovered and developed. One of the significant applications of AI in drug discovery is personalized medicine, where it aids in disease prediction and precision medicine. By analyzing gene data and variant data, AI algorithms can identify potential drug targets and predict their efficacy for specific patient populations. AI also plays a crucial role in drug delivery, drug resistance, and drug safety. It assists in optimizing drug delivery systems, identifying potential drug resistance mechanisms, and monitoring drug safety during clinical development.
Moreover, AI is facilitating biomarker discovery, drug disease association, hit compounds identification, and drug repurposing. It analyzes vast amounts of data from biotechnology and healthcare innovation to identify new drug targets and associations between diseases and drugs. The drug discovery platform is also evolving with AI, enabling faster and more efficient drug development.

Additionally, pharmaceutical innovation continues to thrive with AI, as it streamlines the drug development process, enhances drug design, and supports regulatory compliance. The integration of AI in drug manufacturing and clinical development further accelerates the pace of innovation in the healthcare sector. In conclusion, AI is a game-changer in the drug discovery market, offering numerous benefits from drug structure optimization to regulatory compliance. Its applications in personalized medicine, drug delivery, drug resistance, drug safety, biomarker discovery, and drug development lifecycle are transforming the pharmaceutical industry and driving healthcare innovation.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Deployment

  Cloud-based
  On-premises


Therapeutic Area

  Oncology
  Infectious diseases
  Neurology
  Metabolic diseases
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France


  APAC

    China
    India
    South Korea


  South America



  Middle East and Africa

By Deployment Insights

The cloud-based segment is estimated to witness significant growth during the forecast period.

Artificial Intelligence (AI) plays a crucial role in the drug discovery market, particularly through the application of advanced cloud-based solutions. These technologies offer advantages such as scalability, accessibility, and computational power, enabling companies to accelerate the drug discovery process more effectively. For instance, XtalPi, a global technology company, utilizes AI, quantum physics, and robotics to innovate in life sciences, chemistry, and new materials. By partnering with Amazon Web Services (AWS), XtalPi supports over 150 companies, including 16 of the world's leading pharmaceutical firms, in expediting drug discovery and development. This collaboration underscores the significance of AI in driving innovation and efficiency withi

The drug discovery technologies market is booming, projected to reach $85 billion by 2033, driven by AI, personalized medicine, and rising R&D. Learn about key trends, market size, leading companies (Agilent, GE Healthcare, etc.), and future growth projections in this in-depth analysis.

AI in Drug Discovery Market has valued at USD 750.04 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.18% through 2028

Pages	194
Market Size
Forecast Market Size
CAGR
Fastest Growing Segment
Largest Market
Key Players

The Quantum Computing in Drug Discovery Market Report is Segmented by Deployment Mode (Cloud-Based, On-Premise), Quantum Processing (Gate-Model, Annealers, Photonic, Simulators), Drug Discovery Stage (Target ID, Hit Generation, and More), Therapeutic Area (Oncology, Neurology, and More), End User (Pharmaceutical, Cros, and More), and Geography (North America, Europe, Asia Pacific and More). Market Forecasts in Value (USD).

The AI-enabled drug discovery and clinical trials market worldwide is on the rise. The compound annual growth rate for the period 2019-2030 is expected to be at around ** percent. By 2030, the market is projected to be dominated by North America, generating around ** percent of global market revenues.

The small molecule drug discovery market is booming, driven by technological advancements and increasing demand for novel therapies. Explore market size, growth projections, key players, and emerging trends in this comprehensive analysis, projecting a $150B market by 2033.

Snapshot img

Drug Discovery Informatics Market Size 2024-2028

The drug discovery informatics market size is valued to increase by USD 7.29 billion, at a CAGR of 18.17% from 2023 to 2028. Increasing R and D investments by pharmaceutical and biopharmaceutical companies will drive the drug discovery informatics market.

Market Insights

North America dominated the market and accounted for a 29% growth during the 2024-2028.
By Application - Discovery informatics segment was valued at USD 1.4 billion in 2022
By Solution - Software segment accounted for the largest market revenue share in 2022

Market Size & Forecast

Market Opportunities: USD 382.61 million 
Market Future Opportunities 2023: USD 7287.70 million
CAGR from 2023 to 2028 : 18.17%

Market Summary

The market is a critical segment of the life sciences industry, fueled by the increasing investments in research and development (R&D) by pharmaceutical and biopharmaceutical companies. With the growing number of clinical trials, the need for efficient data management and analysis has become paramount. Drug Discovery Informatics (DDI) solutions enable researchers to integrate, analyze, and interpret complex data from various sources, including genomic, proteomic, and chemical data. Despite its benefits, the high setup cost of DDI systems remains a significant challenge for many organizations. However, the potential for operational efficiency, improved collaboration, and enhanced compliance with regulatory requirements make the investment worthwhile. For instance, a large pharmaceutical company might use DDI to optimize its supply chain by predicting drug shortages based on historical sales data and real-time inventory levels. Moreover, the integration of artificial intelligence (AI) and machine learning (ML) algorithms into DDI platforms is a significant trend, allowing for more accurate predictions and faster identification of potential drug candidates. As the market continues to evolve, the focus on open standards and interoperability will become increasingly important, ensuring seamless data exchange between different systems and facilitating collaboration among stakeholders.

What will be the size of the Drug Discovery Informatics Market during the forecast period?

Get Key Insights on Market Forecast (PDF) Request Free SampleThe market is an ever-evolving landscape that continues to shape the pharmaceutical industry. With advancements in technology, drug discovery informatics has become a crucial component in the development of new therapeutics. This market encompasses various applications, including chemical database management, bioavailability prediction, computational drug design, and drug-target interaction prediction, among others. One trend that has gained significant traction in drug discovery informatics is the adoption of AI-driven approaches. AI-driven drug discovery platforms employ machine learning algorithms and deep learning techniques to analyze vast amounts of data, enabling the prediction of molecular descriptors, drug candidate optimization, and pharmacodynamics modeling. These tools significantly reduce the time and cost associated with traditional drug discovery methods. According to recent studies, the use of AI in drug discovery is projected to increase by 30% in the next five years. This growth is driven by the need for faster and more cost-effective drug development, as well as the growing availability of biological activity datasets and drug discovery analytics. This trend has significant implications for product strategy, as companies must invest in AI-driven drug discovery platforms to remain competitive in the market. Moreover, data visualization tools, cheminformatics libraries, and cheminformatics workflows are essential components of drug discovery informatics, enabling researchers to analyze and interpret complex data. Predictive modeling techniques, such as pharmacokinetics modeling and efficacy prediction models, are also crucial in the drug discovery process, helping to assess drug safety and optimize lead compounds. In conclusion, the market is a dynamic and essential sector that continues to evolve, driven by advancements in technology and the growing need for faster, more cost-effective drug development. The adoption of AI-driven approaches, data visualization tools, and predictive modeling techniques is projected to significantly impact the market in the coming years.

Unpacking the Drug Discovery Informatics Market Landscape

In the realm of drug discovery, informatics plays a pivotal role in enhancing efficiency and accuracy. Conformational analysis methods and pharmacophore modeling techniques facilitate the identification of potential drug candidates, reducing the failure rate in lead optimization by 30%. Drug repurposing databases and ligand-based virtual screening expedite the discovery process, enabli

khairi/drug-discovery-hetionet dataset hosted on Hugging Face and contributed by the HF Datasets community

The global AI drug discovery and development market size is estimated to reach an expected value of USD 8520 million by 2030, registering a CAGR of 31.8% during the forecast period (2022 – 2030), The molecules screening segment is the second largest.
Report Scope:

Report Metric	Details
Market Size in 2021	USD 710 Million
Market Size in 2022	USD XX Million
Market Size in 2030	USD 8520 Million
CAGR	31.8% (2022-2030)
Base Year for Estimation	2021
Historical Data	2018-2020
Forecast Period	2022-2030
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Type,By Indication,By End User,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

According to a survey from 2023, the availability of sufficient/high quality data was*************** stated barrier to the adoption of artificial intelligence (AI) in drug discovery in high-income countries. Other frequently named barriers included the availability of suitable staff and the lack of understanding of AI. This statistic shows the leading barriers for AI adoption in drug discovery in developed countries.

BCC Research Market Report says global market for artificial intelligence in drug discovery is estimated to increase from $1.6 billion in 2023 to $5.7 billion by 2028 at a CAGR of 29.6%.

The data sets available to train models for in silico drug discovery efforts are often small. Indeed, the sparse availability of labeled data is a major barrier to artificial-intelligence-assisted drug discovery. One solution to this problem is to develop algorithms that can cope with relatively heterogeneous and scarce data. Transfer learning is a type of machine learning that can leverage existing, generalizable knowledge from other related tasks to enable learning of a separate task with a small set of data. Deep transfer learning is the most commonly used type of transfer learning in the field of drug discovery. This Perspective provides an overview of transfer learning and related applications to drug discovery to date. Furthermore, it provides outlooks on the future development of transfer learning for drug discovery.

Small Molecule Drug Discovery Market estimated to grow at a CAGR of 8.8%.

The Drug Discovery Informatics Market is expected to witness substantial growth between 2025 and 2035, driven by the increasing integration of artificial intelligence (AI) and machine learning (ML) in drug discovery processes. The market is projected to be valued at USD 16,445.1 million in 2025 and is anticipated to grow to USD 64,814.3 million by 2035, reflecting a compound annual growth rate (CAGR) of 14.7% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 16,445.1 Million
Industry Value (2035F)	USD 64,814.3 Million
CAGR (2025 to 2035)	14.7%

Country wise Outlook

Country	CAGR (2025 to 2035)
USA	14.5%

Country	CAGR (2025 to 2035)
UK	14.3%

Region	CAGR (2025 to 2035)
European Union	15.0%

Country	CAGR (2025 to 2035)
Japan	14.2%

Country	CAGR (2025 to 2035)
South Korea	14.8%

Competitive Outlook

Company Name	Estimated Market Share (%)
PerkinElmer, Inc.	18-22%
Thermo Fisher Scientific, Inc.	14-18%
Certara, L.P.	12-16%
Collaborative Drug Discovery Inc.	8-12%
Novo Informatics	6-10%
Other Companies (combined)	30-40%

The report strategically segments the global biologics drug discovery market based on the phase of discovery, manufacturing type, and product type.

Overview

New York, NY – Oct 20, 2025 – Global Drug Discovery Market size is expected to be worth around USD 77.7 Billion by 2024 from USD 173.5 Billion in 2033, growing at a CAGR of 9.5% during the forecast period 2025 to 2033.

The field of drug discovery continues to play a pivotal role in addressing global health challenges by accelerating the development of innovative therapeutics. Through advancements in biotechnology, artificial intelligence (AI), and genomics, pharmaceutical and biotechnology companies are revolutionizing the process of identifying and developing novel drug candidates.

The global drug discovery landscape is witnessing robust investment and collaboration between research institutions, pharmaceutical firms, and technology providers. AI-driven screening, computational modeling, and high-throughput screening techniques have significantly reduced the time and cost associated with drug identification and testing. Moreover, precision medicine approaches are enabling the development of targeted therapies that improve efficacy and reduce adverse effects.

The integration of bioinformatics, molecular biology, and machine learning has enhanced predictive modeling and compound optimization, leading to improved success rates in clinical trials. Increasing focus on rare diseases, oncology, and neurodegenerative disorders is also expanding the scope of research initiatives.

Regulatory support and strategic partnerships are expected to further drive innovation, ensuring a steady pipeline of new molecules entering preclinical and clinical phases. The future of drug discovery lies in leveraging digital technologies and collaborative ecosystems to deliver safer, more effective, and personalized medicines to patients worldwide.

This transformative progress underscores the industry’s commitment to improving healthcare outcomes through scientific excellence and technological innovation.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_732/https://market.us/wp-content/uploads/2024/10/Drug-Discovery-Market-Size.jpg" alt="Drug Discovery Market Size" class="wp-image-130007">